Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure

NCT01131637 is registered in ClinicalTrials.gov with Zensun Sci. & Tech. Co., Ltd. as lead sponsor.

NCT NCT01131637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01131637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Lead sponsor
Zensun Sci. & Tech. Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2010
Completion date
August 31, 2012
Enrollment
331 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure